Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis

• Published in: The Journal of neuroscience Vol. 11; no. 4; pp. 1016 - 1031
• Main Authors: Gerfen, CR, McGinty, JF, Young, WS, 3d
• Format: Journal Article
• Language: English
• Published: Washington, DC Soc Neuroscience 01.04.1991; Society for Neuroscience
• Subjects: Animals; Biological and medical sciences; Central nervous system; Central neurotransmission. Neuromudulation. Pathways and receptors; Corpus Striatum - cytology; Corpus Striatum - metabolism; Dopamine - pharmacology; Dynorphins - genetics; Dynorphins - metabolism; Enkephalins - genetics; Enkephalins - metabolism; Fundamental and applied biological sciences. Psychology; Histocytochemistry; Immunohistochemistry; Neurons - metabolism; Nucleic Acid Hybridization; RNA, Messenger - metabolism; Substance P - genetics; Substance P - metabolism; Vertebrates: nervous system and sense organs; Immunohistochemistry; Brain; Molecular hybridization; Dopamine; Rat; Substance P; In situ; Rodentia; Enkephalin; Central nervous system; Corpus striatum; Neuropeptide; Vertebrata; Mammalia; Neuromediator; Dynorphin
• ISSN: 0270-6474; 1529-2401
• DOI: 10.1523/jneurosci.11-04-01016.1991

Dopamine regulation of the levels of dynorphin, enkephalin, and substance P messenger RNAs in rat striatal neurons was analyzed with in situ hybridization histochemistry (ISHH). Relative levels of peptide mRNA expression in the patch and matrix compartments of the dorsolateral striatum were compared among control rats, rats treated for 10 d with apomorphine, rats with unilateral 6-hydroxydopamine (6-OHDA) lesions of the nigrostriatal dopaminergic system, and rats with nigrostriatal dopaminergic lesions followed 2 weeks later by 10 d of apomorphine treatment. Image analysis of ISHH labeling demonstrated that the number of neurons expressing each peptide mRNA remained constant, whereas the relative level of peptide mRNA per neuron changed significantly, depending on the experimental treatment. Dynorphin mRNA expression increased following chronic apomorphine treatment: striatal patch neurons increased to an average of 100% above control values, whereas striatal matrix neurons showed only a 25% increase. Dynorphin mRNA expression decreased following 6-OHDA lesions: patch neurons showed an average 75% reduction in expression, whereas matrix neurons showed no significant change. In animals with 6-OHDA lesions followed by apomorphine treatment, both patch and matrix neurons showed an average increase in dynorphin expression of 300% above control levels. Changes in dynorphin mRNA levels with these treatments were matched by qualitative changes in dynorphin immunoreactivity both in the striatum and in striatonigral terminals in the substantia nigra. Neither substance P nor enkephalin mRNA levels showed a significant difference between the striatal patch and matrix compartments in any experimental condition (in the dorsolateral striatum). Substance P mRNA expression was increased an average of 50% after 10 d of apomorphine treatment and showed an average decrease of 75% following 6-OHDA lesions of the mesostriatal system. There was no significant change in the expression of substance P mRNA in striatal neurons compared to control values in rats with combined 6-OHDA lesion and apomorphine treatment. Enkephalin mRNA expression was not significantly altered by chronic apomorphine treatment but showed an average increase per cell of some 130% above control levels following 6-OHDA-induced lesions of the mesostriatal system. In animals with a 6-OHDA lesion and apomorphine treatment, enkephalin mRNA was also elevated but not significantly above the levels produced by the lesions alone. These data show that the expression of dynorphin, enkephalin, and substance P is differentially regulated by the mesostriatal dopaminergic system and, further, suggests that the mechanisms by which this regulation occurs may be different for the 3 peptide families.